Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion
- PMID: 9598830
- DOI: 10.1161/01.atv.18.5.723
Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion
Abstract
Hypertriglyceridemia may contribute to the development of atherosclerosis by increasing expression of cell adhesion molecules (CAMs). Although the cellular expression of CAMs is difficult to assess clinically, soluble forms of CAMs (sCAMs) are present in the circulation and may serve as markers for CAMs. In this study, we examined the association between sCAMs and other risk factors occurring with hypertriglyceridemia, the effect of triglyceride reduction on sCAM levels, and the role of soluble vascular cell adhesion molecule-1 (sVCAM-1) in monocyte adhesion in vitro. Compared with normal control subjects (n=20), patients with hypertriglyceridemia and low HDL (n=39) had significantly increased levels of soluble intercellular adhesion molecule-1 (sICAM-1) (316+/-28.8 versus 225+/-16.6 ng/mL), sVCAM-1 (743+/-52.2 versus 522+/-43.6 ng/mL), and soluble E-selectin (83+/-5.9 versus 49+/-3.6 ng/mL). ANCOVA showed that the higher sCAM levels in patients occurred independently of diabetes mellitus and other risk factors. In 27 patients who received purified n-3 fatty acid (Omacor) 4 g/d for > or =7 months, triglyceride level was reduced by 47+/-4.6%, sICAM-1 level was reduced by 9+/-3.4% (P=.02), and soluble E-selectin level was reduced by 16+/-3.2% (P<.0001), with the greatest reduction in diabetic patients. These results support previous in vitro data showing that disorders in triglyceride and HDL metabolism influence CAM expression and treatment with fish oils may alter vascular cell activation. In a parallel-plate flow chamber, recombinant sVCAM-1 at the concentration seen in patients significantly inhibited adhesion of monocytes to interleukin-1-stimulated cultured endothelial cells under conditions of flow by 27.5+/-7.2%. Thus, elevated sCAMs may negatively regulate monocyte adhesion.
Similar articles
-
Levels of soluble cell adhesion molecules in patients with dyslipidemia.Circulation. 1996 Apr 1;93(7):1334-8. doi: 10.1161/01.cir.93.7.1334. Circulation. 1996. PMID: 8641021
-
Soluble adhesion molecules correlate with surface expression in an in vitro model of endothelial activation.Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):273-9. doi: 10.1111/bcpt.12091. Epub 2013 Jul 6. Basic Clin Pharmacol Toxicol. 2013. PMID: 23724832
-
Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia.Sb Lek. 2001;102(4):473-7. Sb Lek. 2001. PMID: 12448198
-
Inflammation and lipid-lowering treatment.Curr Cardiol Rep. 1999 Sep;1(3):251-5. doi: 10.1007/s11886-999-0031-y. Curr Cardiol Rep. 1999. PMID: 10980850 Review.
-
Review on critical factor in monocyte adhesion: Nutrients.Cytokine. 2025 Feb;186:156845. doi: 10.1016/j.cyto.2024.156845. Epub 2025 Jan 3. Cytokine. 2025. PMID: 39754794 Review.
Cited by
-
Adiposity is associated with endothelial activation in healthy 2-3 year-old children.J Pediatr Endocrinol Metab. 2009 Oct;22(10):905-14. doi: 10.1515/jpem.2009.22.10.905. J Pediatr Endocrinol Metab. 2009. PMID: 20020578 Free PMC article.
-
Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes.Diabetes Care. 2009 May;32(5):932-7. doi: 10.2337/dc08-1856. Epub 2009 Feb 19. Diabetes Care. 2009. PMID: 19228869 Free PMC article.
-
PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?Trans Am Clin Climatol Assoc. 2020;131:42-47. Trans Am Clin Climatol Assoc. 2020. PMID: 32675841 Free PMC article.
-
Serum E-selectin concentration is associated with risk of metabolic syndrome in females.PLoS One. 2019 Sep 24;14(9):e0222815. doi: 10.1371/journal.pone.0222815. eCollection 2019. PLoS One. 2019. PMID: 31550292 Free PMC article.
-
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.Eur J Clin Pharmacol. 2003 Jul;59(3):189-93. doi: 10.1007/s00228-003-0581-7. Epub 2003 May 17. Eur J Clin Pharmacol. 2003. PMID: 12756509 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical